Cargando…
Off-label drug promotion and the ephemeral line between marketing and education
Fueled by massive settlements and concerns about pharmaceutical company influence over medical practice, the fight over off-label promotion has become a rancorous one with little middle ground. For some, off-label restrictions are both bad law and bad medicine, violating the First Amendment while de...
Autor principal: | Krause, Joan H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034393/ https://www.ncbi.nlm.nih.gov/pubmed/27774219 http://dx.doi.org/10.1093/jlb/lsv052 |
Ejemplares similares
-
The off-label use, utility and potential value of tDCS in the clinical care of particular neuropsychiatric conditions
por: Bikson, Marom, et al.
Publicado: (2016) -
Regulating drug promotion to promote the public health: a response to Bennett et al.
por: Zettler, Patricia J.
Publicado: (2015) -
The problems of liminal states, line drawing, and false dichotomies
por: Suter, Sonia
Publicado: (2015) -
Modernizing biomedical regulation: foresight and values in the promotion of responsible research and innovation
por: Harmon, Shawn H.E.
Publicado: (2016) -
Orphan drug incentives in the pharmacogenomic context: policy responses in the USA and Canada
por: Herder, Matthew
Publicado: (2016)